



Oscotec R&D Day

July 8, 2026

Translating Science into Medicine

Disclaimer

- This presentation has been prepared by Oscotec Inc.(the “Company”) solely for its own use at its presentation to company investors.
- Information contained herein is strictly confidential and is given only for your information and for your use and may not be copied, reproduced, distributed, redistributed or passed on, directly or indirectly, to any other person in any manner, or published, in whole or in part, for any purpose. Certain statements contained herein constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “anticipates,” “plans,” “estimates,” “expects” and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings.
- **Forward-looking statements** are not guarantees of future performance and involve certain uncertainties and risks, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors including but not limited to the changes in market conditions and strategy revisions.
- The Company is not liable for any investment decisions by its readers or subscribers and does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.

3 Deals in 6 months

오스코텍, 사노피에 1.5조 규모 기술이전 성공...타우 타깃 신약후보 'ADEL -Y01'

(주)아델과 공동 연구개발한 알츠하이머 치료제 '1.5조원 규모' 사노피에 기술이전
윤태영 대표, “레이저티닙 이후를 겨냥한 ‘오픈 이노베이션 전략’의 첫 결실”

입력 2025-12-16 10:08

오스코텍, 美야티리와 'FLT3/AXL 저해제' AML 옵션딜

기사입력 : 2026-03-25 11:06 | 수정 : 2026-03-25 11:16

오스코텍, 세비도플레닙 美 아지오스에 1조원 규모 기술이전...글로벌 개발 본격화

등록 2026-06-01 오후 4:22:08

수정 2026-06-01 오후 4:22:08

2026 R&D Pipeline

Program	MoA	Indication	Discovery	Lead Opt	Preclinical	Phase I	Phase II	Phase III	Partner
Cevidoplenib (SKI-O-703)	SYK	RA							
		ITP							
Denfivontinib (SKI-G-801)	FLT3/AXL	AML							
		Solid tumors							
ADEL-Y01	Anti-TAU mAb	Alzheimer							
OCT-598	EP2/4	ACART*							
OCT-648	NUAK1	Fibrosis							
ONC1	NUAK1/2	ACART*							
ONC2	(Undisclosed)	ACART*							
ONC3	(Undisclosed)	ACART*							

(*ACART = Anti Cancer Anti Resistance Therapy)

OCT-598 for Cancer Chemoresistance

- History


- An EP2/4 dual antagonist, anticipated to help overcome **cancer therapy resistance** and immune evasion
- In-licensed from Kanaph Therapeutics in 2022
- Preclinical data presented at AACR 2023 and 2025

- Current Status

- Part A (3 sites, KR) 200 mg cohort ongoing
- Part B (5+3 sites, KR/US) being readied

- Prospect



- Chemocombination PK/safety to be confirmed
- Readout for potential docetaxel-combination efficacy signal by 1Q2027
- Expansion to SoC combination in mCRC in 2027



* PK = pharmacokinetics; SoC = standard-of-care; CRC = colorectal cancer

OCT-648 for Kidney Fibrosis

- What it is
 - Highly selective NIAK1 inhibitor
 - Hypothesis;
 - NIAKs perpetuates chronic YAP activation
 - YAP mediates protective polyploidization of tubular cells that leads to long-term fibrosis and CKD
- Current Status
 - Initial PoC in mouse CKD models (UUO)
 - Preclinical data presented at WCN 2026
 - Lead opt to increase odds of success
 - Multiple translational studies incl AKI-to-CKD
- Prospect
 - Candidate selection in 2H2026
 - Early L/O potential along with GNS-3545 in P1



* PoC = Proof-of-Concept; CKD = chronic kidney disease; UUO = unilateral ureteral obstruction; WCN = World Congress of Nephrology; AKI = acute kidney injury; L/O = license out



ACART


Anti-Cancer Anti-Resistance Therapy

Translating Science into Medicine

Problem to Solve


Most tumors **relapse** after treatment and relapsed tumors are more malignant and lethal, potentially accelerating the progression afterwards

Prostate Cancer



Imamura & Sadar, Int. J. Urology 2016

Ovarian Cancer




Giornelli & Mando, Eur Med J 2017

← Tumor-selective cell-killing by itself is NO solution!


ACART; Targeting Polyploidy-Mediated Therapy Resistance

Therapy-Induced PGCC Formation and Repopulation as a Targetable Resistance Cycle



ACART captures both PGCC formation blockade and suppression of PGCC-driven repopulation

Targeting Survival, Evolution, and Repopulation after Therapy




ACART captures both PGCC formation blockade and suppression of PGCC-driven repopulation

Rybrevant-Lazcluze; the Secret of Success?

- Amivantamab targets both EGFR and c-MET
- MET overexpression/amplification long known to be an important bypass mechanism in EGFR TKI resistance
- METi/EGFRi combination have shown limited, if any, efficacy in clinical trials in the 2nd line, TKI-resistant setting
 - Tepotinib/gefitinib vs chemo; **mPFS 4.9 mo vs 4.4 mo**
 - 2L Amivantamab/lazertinib **mPFS 4.9 mo**
- HGF/c-MET axis is a critical promoter of liver regeneration


Prevention vs reversion of resistance?




Lyfyorli® in Pt-resistant Ovarian Cancer

- Relacorilant, a glucocorticoid receptor antagonist (Corcept) approved by FDA on March 2026
- In P3, improved OS by 4.1 months in combi with nab-ptx compared to nab-ptx alone
- In comparison, another GR antagonist ORIC-101 has failed as a nab-ptx combination in P1b study for patients who were previously treated and progressed on taxane-based regimen
- Mifepristone (PR/GR antagonist) was shown to inhibit polyploidy-mediated cancer therapy resistance

Prevention vs reversion of resistance?









ACART Platform; Navigating the T3 Space




- High throughput high contents screening with AI-assisted single-cell morpholomics
- Target discovery by systems biology network model from staged scRNAseq
- Current focus on;
 - FOLFIRI-resistance of MSS mCRC
 - TMZ-resistance of glioblastoma
 - Sotorasib-resistance of KRAS G12C NSCLC


Single Cell Morpholomics




High Throughput High Contents Screening



Dr. Regis Grailhe



The Best is Yet to Come



Confidential



Translating Science into Medicine

